Results for:(59 found)
Feb 6, 2013 2:03PM on Top StocksBy MSN Money Partner

Stocks are almost unchanged following 3 straight days of triple-digit moves for the Dow.

Feb 1, 2013 9:57AM on Top StocksBy Minyanville.com

The month also features a big gathering of biotech CEOs in New York and a cancer research meeting in Florida.

Jan 28, 2013 8:11AM on Top StocksBy Benzinga

Caterpillar, Yahoo and a few other companies report earnings.

Jan 3, 2013 2:17PM on Top StocksBy Minyanville.com

Shares are dropping after the big biotech says it's scrapping an R&D program for ALS. But a new pill for multiple sclerosis continues to be the major catalyst for this stock.

Tags: BIIBNVS
Jan 3, 2013 12:17PM on Top StocksBy MSN Money Partner

SunPower is upgraded to 'buy,' and Biogen is downgraded to 'neutral.'

Jan 2, 2013 12:07PM on Top StocksBy TheStreet Staff

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.

Dec 27, 2012 11:51AM on Top StocksBy Minyanville.com

Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.

Nov 21, 2012 12:04PM on Top StocksBy MSN Money Partner

Skechers is upgraded to 'positive,' and Yum Brands is initiated with an 'outperform.'

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More